Clinical Trial Update: A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. [Phase 2]

View source ↗

Summary

A Phase II trial of Anlotinib with platinum-based chemotherapy for SMARCA4-deficient locally advanced or metastatic lung cancer. Not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Smarca4-deficient Tumor

Drugs mentioned

• Anlotinib (anlotinib)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Zhijie Wang | Conditions: SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING